RxDoctor Payments Data

Bonnie Woo, MD

Ophthalmology · City Of Industry, CANPI 1841222536

Payments from drug & device makers

$2,602in general payments, 2019–2025

Across 123 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$531
  • Sun Pharmaceutical Industries Inc.$335
  • Amgen$211
  • Oyster Point Pharma, Inc.$209
  • AbbVie$197
  • Bausch & Lomb Americas Inc.$186
  • plus $932 from 14 others

What the payments were for

  • Food & beverage$2,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,602 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$203,019
Medicare patients
558
Services billed
1,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine291$259,150
Cyclosporine434$211,141
XiidraLifitegrast88$94,179
LumiganBimatoprost99$37,101
RocklatanNetarsudil Mesylat/Latanoprost60$33,745
BesivanceBesifloxacin Hcl140$29,930
Bromfenac Sodium129$27,047
SimbrinzaBrinzolamide/Brimonidine Tart103$26,213
ProlensaBromfenac Sodium61$20,030
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol105$19,749
Travoprost145$19,385
VyzultaLatanoprostene Bunod60$19,053
Brimonidine Tartrate253$16,744
Prednisolone Acetate486$12,871
RhopressaNetarsudil Mesylate33$11,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$197$310,663432 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$186$113,232148 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa$125$49,960201 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$149$45,73193 claims
AlconSimbrinza$531$26,213103 claims
Sun Pharmaceutical Industries Inc.Cequa$335$6,27211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in City Of Industry

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →